Abstract
98TiP Safety and efficacy of aumolertinib combined with anlotinib as 1st-line treatment in advanced lung cancer EGFR mutation with TP53 co-mutation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have